BRPI0815324A2 - "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" - Google Patents
"conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"Info
- Publication number
- BRPI0815324A2 BRPI0815324A2 BRPI0815324-8A BRPI0815324A BRPI0815324A2 BR PI0815324 A2 BRPI0815324 A2 BR PI0815324A2 BR PI0815324 A BRPI0815324 A BR PI0815324A BR PI0815324 A2 BRPI0815324 A2 BR PI0815324A2
- Authority
- BR
- Brazil
- Prior art keywords
- saccharide
- containing protein
- protein conjugate
- pharmaceutical composition
- separating
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title 5
- 102000004169 proteins and genes Human genes 0.000 title 5
- 108090000623 proteins and genes Proteins 0.000 title 5
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93558707P | 2007-08-20 | 2007-08-20 | |
| PCT/IL2008/001143 WO2009024977A2 (en) | 2007-08-20 | 2008-08-20 | Saccharide-containing protein conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0815324A2 true BRPI0815324A2 (pt) | 2015-07-14 |
Family
ID=40227632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815324-8A BRPI0815324A2 (pt) | 2007-08-20 | 2008-08-20 | "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8742079B2 (pt) |
| EP (1) | EP2192924B1 (pt) |
| AU (1) | AU2008290217B2 (pt) |
| BR (1) | BRPI0815324A2 (pt) |
| CA (1) | CA2696699A1 (pt) |
| IL (1) | IL204037A (pt) |
| WO (1) | WO2009024977A2 (pt) |
| ZA (1) | ZA201001206B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0815324A2 (pt) | 2007-08-20 | 2015-07-14 | Protalix Ltd | "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" |
| JP5837486B2 (ja) | 2009-07-03 | 2015-12-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | カチオン非依存性マンノース６−リン酸受容体を標的とする化合物 |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| EP2507629B1 (en) | 2009-12-01 | 2016-03-09 | Shire Human Genetic Therapies, Inc. | Enzymatic activity-based detection |
| US20120328589A1 (en) | 2010-03-02 | 2012-12-27 | Ilya Ruderfer | Glucocerebrosidase multimers and uses thereof |
| JP5758920B2 (ja) * | 2010-03-02 | 2015-08-05 | プロタリクス リミテッド | 安定化α−ガラクトシダーゼおよびその使用 |
| WO2012015681A2 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| CA2807942C (en) | 2010-08-10 | 2021-07-27 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011356137A1 (en) | 2011-01-20 | 2013-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| EP2718459B1 (en) | 2011-06-08 | 2018-02-28 | Shire Human Genetic Therapies, Inc. | Competition-based detection assays |
| SG10201906382QA (en) * | 2013-05-01 | 2019-08-27 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv and ttr expression |
| US10751425B2 (en) * | 2014-01-15 | 2020-08-25 | Baseclick Gmbh | Saccharide-modified nucleic acid molecules |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| BR112019013920A2 (pt) | 2017-01-05 | 2020-02-04 | Protalix Ltd | método para tratar doença de fabry, e, forma unitária de dosagem. |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EP3756017A1 (en) * | 2018-02-23 | 2020-12-30 | Julius-Maximilians-Universitaet Wuerzburg | Compounds and methods for the detection of fabry disease |
| EP3790577A4 (en) * | 2018-05-09 | 2022-04-27 | The University of Chicago | COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE |
| CN114748685A (zh) * | 2022-04-24 | 2022-07-15 | 华中农业大学 | 具有促进烫伤和急性创面愈合功能的水凝胶制备方法及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
| US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| US5936035A (en) | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
| US5179023A (en) * | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| DE4009630C2 (de) * | 1990-03-26 | 1995-09-28 | Reinhard Prof Dr Dr Brossmer | CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| WO1993018148A2 (en) | 1992-03-12 | 1993-09-16 | Wisnieski Bernadine J | Tumor necrosis factor with modified channel activity |
| EP0665852A1 (en) | 1993-07-09 | 1995-08-09 | Amgen Boulder Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| US6329191B1 (en) | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5994086A (en) * | 1994-03-30 | 1999-11-30 | North Shore University Hospital | Method for assessing infertility by binding of mannose to sperm cells |
| EP0807165A4 (en) | 1995-01-30 | 1998-07-15 | New York Blood Center Inc | ENZYME -g (a) -GALACTOSIDASE RECOMBINANT |
| WO1997010353A1 (en) | 1995-09-14 | 1997-03-20 | Virginia Tech Intellectual Property, Inc. | Production of lysosomal enzymes in plant-based expression systems |
| US6309646B1 (en) * | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| IL119310A (en) | 1996-09-26 | 1999-07-14 | Metabogal Ltd | Cell/tissue culturing device and method |
| US20010008766A1 (en) * | 1998-03-17 | 2001-07-19 | Sylvia Daunert | Quantitative binding assays using green fluorescent protein as a label |
| IL125423A (en) * | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
| AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
| US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| JP2004525621A (ja) | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | グルコセレブロシダーゼ活性を有する二機能性融合タンパク質 |
| ATE329930T1 (de) | 2001-10-22 | 2006-07-15 | Applied Research Systems | Fsh-zusammensetzungen mit hohem sialylierungsgrad und deren verwendung zur herstellung von arzneimitteln |
| CA2467052A1 (en) | 2001-11-16 | 2003-05-22 | Pharmexa A/S | Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts |
| EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| EP1523548B1 (en) | 2002-05-15 | 2009-12-30 | Agricultural Research Organization | Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| EP1613264A4 (en) | 2003-04-16 | 2007-08-15 | Yeda Res & Dev | MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| GB2402677A (en) | 2003-05-06 | 2004-12-15 | Sirus Pharmaceuticals Ltd | Biodegradable polymer |
| WO2004111198A2 (en) | 2003-06-12 | 2004-12-23 | Genzyme Corporation | Modified human acid sphingomyelinase having increased activity, and methods for making the same |
| JP2005043317A (ja) | 2003-07-25 | 2005-02-17 | Olympus Corp | 糖鎖と生体分子との反応を検出する方法 |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| CA2545276C (en) * | 2003-11-05 | 2016-05-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| US20080015142A1 (en) | 2003-12-03 | 2008-01-17 | Defrees Shawn | Glycopegylated Follicle Stimulating Hormone |
| AU2005211775B2 (en) * | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| US8273357B2 (en) * | 2004-07-16 | 2012-09-25 | Massachusetts Institute Of Technology | Antigen-carbohydrate conjugates |
| PL1877099T3 (pl) * | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
| EP1904638A2 (en) | 2005-07-18 | 2008-04-02 | Metabogal Ltd. | Mucosal or enteral administration of biologically active macromolecules |
| KR20070065157A (ko) | 2005-12-19 | 2007-06-22 | 이수근 | 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법 |
| US8299026B2 (en) * | 2006-07-25 | 2012-10-30 | Lipoxen Technologies Limited | Derivatisation of erythropoietin (EPO) |
| US20100144008A1 (en) | 2006-12-21 | 2010-06-10 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
| ES2744574T3 (es) * | 2007-01-18 | 2020-02-25 | Genzyme Corp | Oligosacáridos que comprenden un grupo aminooxi y conjugados de los mismos |
| BRPI0815324A2 (pt) | 2007-08-20 | 2015-07-14 | Protalix Ltd | "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" |
| EP2339951A1 (en) | 2008-07-10 | 2011-07-06 | Given Imaging Ltd. | Device, method and kit for in vivo detection of a biomarker |
| US20120230974A1 (en) * | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| US20120328589A1 (en) | 2010-03-02 | 2012-12-27 | Ilya Ruderfer | Glucocerebrosidase multimers and uses thereof |
| AU2011356137A1 (en) | 2011-01-20 | 2013-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
-
2008
- 2008-08-20 BR BRPI0815324-8A patent/BRPI0815324A2/pt not_active IP Right Cessation
- 2008-08-20 CA CA2696699A patent/CA2696699A1/en not_active Abandoned
- 2008-08-20 WO PCT/IL2008/001143 patent/WO2009024977A2/en not_active Ceased
- 2008-08-20 US US12/673,987 patent/US8742079B2/en not_active Expired - Fee Related
- 2008-08-20 AU AU2008290217A patent/AU2008290217B2/en not_active Ceased
- 2008-08-20 EP EP08789815.1A patent/EP2192924B1/en not_active Not-in-force
-
2010
- 2010-02-18 IL IL204037A patent/IL204037A/en not_active IP Right Cessation
- 2010-02-19 ZA ZA2010/01206A patent/ZA201001206B/en unknown
-
2014
- 2014-05-20 US US14/281,981 patent/US20140256017A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL204037A (en) | 2016-10-31 |
| US20110105379A1 (en) | 2011-05-05 |
| AU2008290217A1 (en) | 2009-02-26 |
| WO2009024977A2 (en) | 2009-02-26 |
| EP2192924B1 (en) | 2017-10-11 |
| AU2008290217B2 (en) | 2013-09-05 |
| ZA201001206B (en) | 2010-12-29 |
| WO2009024977A3 (en) | 2010-01-28 |
| EP2192924A2 (en) | 2010-06-09 |
| CA2696699A1 (en) | 2009-02-26 |
| US8742079B2 (en) | 2014-06-03 |
| US20140256017A1 (en) | 2014-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815324A2 (pt) | "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos" | |
| BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
| BRPI0717695A2 (pt) | "composição, uso de uma compsição e processo de preparação de uma composição" | |
| BRPI0906064A2 (pt) | "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)" | |
| BRPI0719488A2 (pt) | "composição, processo de preparação da composição, uso de uma composição e uso cosmético de uma composição" | |
| BRPI0905663A2 (pt) | "emulsão estável, processo de preparação da emulsão estável e uso emulsão" | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0719497A2 (pt) | "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição" | |
| BRPI0815079A2 (pt) | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto | |
| EP2149361A4 (en) | OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0815360A2 (pt) | Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto | |
| BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
| BRPI0717699A2 (pt) | "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição! | |
| CR10229A (es) | Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| BRPI0716703A2 (pt) | "composiÇço, fluidos funcionais e processo de preparaÇço de uma composiÇço" | |
| CL2007002376A1 (es) | Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas. | |
| BRPI0914371A2 (pt) | "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação" | |
| BRPI0811826A2 (pt) | ''uso de composto organosfosforado, artigo e processo de fabricação de um artigo | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
| EP2155792A4 (en) | PROTEIN G-OLIGONUCLEOTIDE CONJUGATE | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
| CL2007003593A1 (es) | Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina. | |
| EP2366691A4 (en) | NITROPYRIDINYLETHYLENIMINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | |
| BRPI1011822A2 (pt) | "compostos de 3-substituída-8-substituída-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona e sua aplicação" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 60/935,587 DE 20/08/2007, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL. |
|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/54 (2017.01), A61P 43/00 (2006.01) |